Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The study sought to observe the effects of optimal dose of ticagrelor（90 mg qd）ticagrelor and
double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients
with high on-treatment platelet reactivity (HTPR) while on clopidogrel.
HTPR with clopidogrel administration in coronary heart disease (CHD) patients has associated
with an increased risk of adverse events. Newer P2Y12 inhibitors ticagrelor (90mg BID)
provide stronger platelet inhibition compared with clopidogrel, but a low-dose of ticagrelor
(90mg QD) has not been previously studied in Chinese CHD patients with HTPR.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University